- Home
- BCTXW vs OUT Comparison
BCTXW vs OUT Comparison
Compare BCTXW & OUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTXW
- OUT
- Stock Information
- Founded
- BCTXW N/A
- OUT 2013
- Country
- BCTXW Canada
- OUT United States
- Employees
- BCTXW 12
- OUT N/A
- Industry
- BCTXW Biotechnology: Pharmaceutical Preparations
- OUT Real Estate Investment Trusts
- Sector
- BCTXW Health Care
- OUT Real Estate
- Exchange
- BCTXW Nasdaq
- OUT Nasdaq
- Market Cap
- BCTXW N/A
- OUT N/A
- IPO Year
- BCTXW N/A
- OUT N/A
- Fundamental
- Price
- BCTXW $0.34
- OUT $18.33
- Analyst Decision
- BCTXW
- OUT Hold
- Analyst Count
- BCTXW 0
- OUT 5
- Target Price
- BCTXW N/A
- OUT $19.25
- AVG Volume (30 Days)
- BCTXW N/A
- OUT 2.0M
- Earning Date
- BCTXW N/A
- OUT 11-12-2024
- Dividend Yield
- BCTXW N/A
- OUT 9.12%
- EPS Growth
- BCTXW N/A
- OUT N/A
- EPS
- BCTXW N/A
- OUT 1.38
- Revenue
- BCTXW N/A
- OUT $1,838,900,000.00
- Revenue This Year
- BCTXW N/A
- OUT N/A
- Revenue Next Year
- BCTXW N/A
- OUT $2.00
- P/E Ratio
- BCTXW N/A
- OUT $13.32
- Revenue Growth
- BCTXW N/A
- OUT 1.37
- 52 Week Low
- BCTXW N/A
- OUT $12.27
- 52 Week High
- BCTXW N/A
- OUT $19.50
- Technical
- Relative Strength Index (RSI)
- BCTXW N/A
- OUT 40.54
- Support Level
- BCTXW N/A
- OUT $18.08
- Resistance Level
- BCTXW N/A
- OUT $19.10
- Average True Range (ATR)
- BCTXW 0.00
- OUT 0.36
- MACD
- BCTXW 0.00
- OUT -0.10
- Stochastic Oscillator
- BCTXW 0.00
- OUT 16.54
About BCTXW BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.